

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of : Attorney Docket No. 333169.00100
 :
 Ruoxing Wang *et al* : Customer No. 27160
 :
 Application No.: 10/510,148 : Group Art Unit:
 :
 Filed: October 5, 2004 : Examiner: Unassigned

Title: REGULATORY ELEMENTS IN THE TREATMENT OF DISEASE AND THE DISCOVERY OF
 THERAPEUTICS

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
 APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
 SEQUENCE DISCLOSURES UNDER 37 C.F.R. §1.821(e), §1.821(f), AND §1.825(b)
 AND PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Commissioner of Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Commissioner:

In response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under C.F.R. §1.821(e), §1.821(f), and §1.825(b) dated April 15, 2005, please enter the following Preliminary Amendment in the above-identified application and consider the remarks below. Submitted herewith is: (a) Exhibit A, a paper copy and computer readable form (CRF) of the sequencing listing submitted in accordance with 37 C.F.R. §§ 1.82(c) and (e).

Applicants petition the Commissioner for Patents to extend the time for response for one month from June 15, 2005 to July 15, 2005. A fee of \$60 is to be charged to Deposit Account No. 50-1710. Any deficiency in or overpayment of this fee should be charged or credited to Deposit Account No. 50-1710.

PRELIMINARY AMENDMENT

IN THE SPECIFICATION:

Please enter the Sequence Listing on page 42, after the Claims.

STATEMENT UNDER 37 C.F.R. § 1.821(f)

In accordance with 37 CFR §§ 1.821-1.825, Applicants hereby state that the content of the paper and computer-readable copies of the sequence listing submitted in accordance with 37 CFR §§ 1.82(c) and (e) respectively, are the same. Applicants hereby state that this submission, filed in accordance with 37 CFR § 1.82 (g), does not introduce new matter.


REMARKS

Consistent with the Sequence Listing filed concurrently herewith, applicants amend the Specification of the instant application as indicated above. No new matter is believed to be at issue, and entry and early action on the merits are respectfully requested.

AUTHORIZATION

The Commissioner is hereby authorized to charge any deficiencies in the associated fees which may be required for this Preliminary Amendment, or credit any overpayment to deposit account no. 50-1710.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Serge Sira', is written over a horizontal line.

Serge Sira, Ph.D.
Registration No. 39,445

Dated: July 5, 2005

Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street
Chicago, Illinois 60661-3693
Facsimile: (312) 902-1061




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

DOCKETED	
U.S. APPLICATION NO. 10/510,148	FIRST NAMED APPLICANT Ruoxing Wang
Action Type Response	ATTY. DOCKET NO. 333169.00100
Due/Final 6/15/05	INTERNATIONAL APPLICATION NO. PCT/US03/10536
Atty Gm/1/05 Sec	LA. FILING DATE 04/07/2003
Docketed by Dee Date 4/22/05	PRIORITY DATE 04/05/2002

27160

KATTEN MUCHIN ZAVIS ROSENMAN
 525 WEST MONROE STREET
 CHICAGO, IL 60661-3693



CONFIRMATION NO. 6425
 371 FORMALITIES LETTER



OC000000015755545

Date Mailed: 04/15/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/510,148	PCT/US03/10536	333169.00100

FORM PCT/DO/EO/922 (371 Formalities Notice)